The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A single-arm, open-label phase 2 trial of doxorubicin plus zalifrelimab, a CTLA-4 inhibitor, with balstilimab, a PD-1 inhibitor, in patients with advanced/metastatic soft tissue sarcomas.
 
Breelyn A. Wilky
Consulting or Advisory Role - Adaptimmune; Adcendo; Boehringer Ingelheim; Daiichi Sankyo; Deciphera; Epizyme; Polaris; SpringWorks Therapeutics
Research Funding - Agenus; Exelixis
Travel, Accommodations, Expenses - Adaptimmune; Daiichi Sankyo; Deciphera
 
Alessandra Maleddu
No Relationships to Disclose
 
Anne Mailhot
Consulting or Advisory Role - Deciphera; SpringWorks Therapeutics
 
Chelsey Cartwright
No Relationships to Disclose
 
Dexiang Gao
No Relationships to Disclose
 
Cristiam Moreno Tellez
No Relationships to Disclose
 
Kyle Powers
No Relationships to Disclose
 
Lindsey Kemp
No Relationships to Disclose
 
Nicholas Therrien
No Relationships to Disclose
 
Jaymin M. Patel
Employment - Agenus
Leadership - Agenus
Stock and Other Ownership Interests - Agenus
 
Joseph Elan Grossman
Employment - Agenus
Stock and Other Ownership Interests - Agenus
 
Steven O'Day
Employment - Agenus
Leadership - Agenus
Stock and Other Ownership Interests - Agenus
 
Anthony D. Elias
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Agilent; Alexion Pharmaceuticals; Align Oncology; Allergan; Amgen; Biogenerix; Bristol-Myers Squibb; Cigna; Exact Sciences; Gilead Sciences; Illumina; Lilly; Merck; Pfizer; United Health Group
Research Funding - Astellas Pharma (Inst); BioAtla (Inst); Deciphera (Inst); Genentech (Inst); Infinity Pharmaceuticals (Inst); Karyopharm Therapeutics (Inst); Orinove (Inst); TopAlliance BioSciences Inc (Inst); xencor (Inst)
(OPTIONAL) Uncompensated Relationships - Seiyax